Colonisation Resistance Study

NCT ID: NCT01507935

Last Updated: 2012-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is initiated to investigate the effect of infant formulas with added specific prebiotic oligosaccharides on the reduction of specific potential pathogens and/or toxins.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Infants

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy infants Infant formula Prebiotics oligosaccharides Colonisation Resistance Gut Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group I

Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I

Group Type ACTIVE_COMPARATOR

Regular non-hydrolysed cow's milk

Intervention Type OTHER

Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I

Intervention Group II

Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II

Group Type ACTIVE_COMPARATOR

Regular non-hydrolysed cow's milk

Intervention Type OTHER

Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II

Control Group

Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides

Group Type PLACEBO_COMPARATOR

Regular non-hydrolysed cow's milk

Intervention Type OTHER

Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides

Reference group

Exclusively breast-fed infants

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regular non-hydrolysed cow's milk

Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I

Intervention Type OTHER

Regular non-hydrolysed cow's milk

Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II

Intervention Type OTHER

Regular non-hydrolysed cow's milk

Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy term infants (gestational age 37 to 42 weeks) aged 2-2.5 months at inclusion
* Fully formula fed for at least one week (not applicable for the breastfeeding reference group since these infants must be exclusively breastfed before and throughout the study)
* Parents' or guardian's written informed consent

Exclusion Criteria

* Being weaned before inclusion (introduction of any other foods other than formula or breast milk.)
* Moderate or severe acute malnutrition, defined as weight-for-age and sex below -2 z-scores of the median WHO growth standards
* Disorders requiring a special diet (such as food intolerance or food allergy or complaints such as reflux, constipation and cramps)
* Significant congenital abnormality that could affect the study results
* Use of systemic antibiotics or anti-mycotic drugs in the 4 weeks preceding the study
* Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements
* Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
* Gastroenteritis in the last two weeks before inclusion
Minimum Eligible Age

8 Weeks

Maximum Eligible Age

10 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danone Global Research & Innovation Center

INDUSTRY

Sponsor Role collaborator

Danone Asia Pacific Holdings Pte, Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sungkom Jongpiputvanich, A/Prof., MD.

Role: PRINCIPAL_INVESTIGATOR

Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

Site Status

Phramongkutklao Hospital

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COL.1.C/A

Identifier Type: -

Identifier Source: org_study_id